NEWS & UPDATES

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to
Read more.
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA
Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA
Read more.
Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease
CHICAGO, August 21, 2017   Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that
Read more.
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease
 Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases  Osaka, Japan, December 8, 2015,
Read more.
Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease
Proprietary antigen-specific nanoparticles and cure for celiac disease Chicago (June 22, 2015) – Cour Pharmaceutical Development Company today announced new
Read more.